Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking approach to diabetes management. These innovative therapies work by mimicking the inherent actions of GLP-1, a hormone secreted by the gut in response to meals. By activating GLP-1 receptors in the pancreas, these substances increase insulin release and reduce glucagon

The burgeoning landscape of emerging treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting significant weight decrease – they exhibit intriguing variations in their ph